

Applicant: Graham P. Allaway et al.
Serial No: 09/724,105
Filed : November 28, 2000

In the abstract:

Please renumber page 89 containing the abstract as page 81.

Remarks

Applicants have hereinabove deleted pages 74-81 containing the sequence listing. Applicants have attached a replacement sequence listing as **Exhibit B**. Applicants have renumbered pages 82-88 containing the claims as pages 74-80 and renumbered page 89 containing the abstract as page 81. This amendment does not involve any issue of new matter and entry is respectfully requested.

In the May 4, 2001 Notice To Comply, the Examiner stated that the application filed November 28, 2000 is not fully responsive to the prior Office action because of the following omission(s) or matter(s):

The Examiner stated that this application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(f), 1.821 (g), 1.825(b), or 1.825(d). The Examiner stated that applicant must provide such statement. The Examiner stated that a copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). The Examiner stated that applicant must provide an initial computer readable for (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f),

Applicant: Graham P. Allaway et al.
Serial No: 09/724,105
Filed : November 28, 2000

1.821(g), 1.825(b), or 1.825(d). The Examiner stated that if applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

In response, applicants submit a paper copy of the Sequence Listing attached hereto as **Exhibit B** in compliance with the requirements of 37 C.F.R. §1.824. In addition applicants submit herewith a substitute computer readable form (CRF) copy of the "Sequence Listing" as required by 37 C.F.R. §1.825(d). Further, applicants submit herewith as **Exhibit C** a statement in accordance with 37 C.F.R. §1.821(f), certifying that the substitute computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which was submitted as the "Sequence Listing" and contains no new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invites the Examiner to telephone them at the number provided below.


Applicant: Graham P. Allaway et al.
Serial No: 09/724,105
Filed : November 28, 2000

No fee is deemed necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

 6-28-01
John P. White Date
Reg. No. 28,678
Spencer H. Schneider
Reg. No. 45,923

John P. White
Registration No. 28,678
Spencer H. Schneider
Registration No. 45,923
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400